Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ACOT9
REST API REST API
Homo sapiens
ACOT9 is differentially expressed in 279 experiments: 135 organism parts: lung, cerebellum, ... (133 more);, 193 disease states: normal, cervical carcinoma, ... (191 more);, 90 cell types 337 cell lines 22 compound treatments and 71 other conditions.
Synonyms CGI-16, MT-ACT48, ACATE2
Orthologs ACOT9 (Gallus gallus)   Acot9 (Mus musculus)   ACOT9_BOVIN (Bos taurus)   acot9.2 (Danio rerio)   acot9.1 (Danio rerio)   Acot10 (Mus musculus)   ENSCING00000007828 (Ciona intestinalis)   Acot9 (Rattus norvegicus)   CG1774 (Drosophila melanogaster)   CG1635 (Drosophila melanogaster)   CG1638 (Drosophila melanogaster)   CG13771 (Drosophila melanogaster)   acot9 (Xenopus laevis)   ACOT9 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term acyl-CoA metabolic process, carboxylesterase activity, hydrolase activity, mitochondrion, acetyl-CoA hydrolase activity
InterPro Term Thioestr_supf
UniProt Accession Q9Y305, Q96EA2, Q9H2R8, C9J7L8, F8WDI2
Search EB-eye ENSG00000123130
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
HepG2
3
E-GEOD-7307, E-GEOD-21154, E-MTAB-37
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
HL-60
2
E-GEOD-5258, E-GEOD-24147
Jurkat
2
E-MEXP-2197, E-MTAB-62
LNCaP
2
E-GEOD-14990, E-GEOD-14464
331 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-20193, E-GEOD-22373, E-MEXP-2426, E-GEOD-21668, ... (45 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
adipocyte
2
E-AFMX-5, E-TABM-145
memory B cell
2
E-MEXP-2360, E-TABM-702
macrophage
1
2
E-GEOD-22373, E-GEOD-5099, E-GEOD-3982
monocyte
1
2
E-GEOD-11755, E-GEOD-22373, E-GEOD-5099
CD8+ naive CD8 T cell
1
E-TABM-40
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-12254, E-MTAB-62, ... (63 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-62, E-GEOD-5823, E-MEXP-1331
breast carcinoma
2
E-GEOD-5823, E-TABM-276
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-GEOD-3726, E-MTAB-62
colorectal adenocarcinoma
2
E-AFMX-5, E-MTAB-62
control
2
E-GEOD-21912, E-GEOD-20602
187 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (17 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
CNOT7+CNOT8
1
1
E-MEXP-2218
unknown
1
E-GEOD-7307
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
Cxcl12
1
E-GEOD-7307
bacterial endotoxin
1
E-GEOD-3284
16 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-22513, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-1561, E-GEOD-22148, E-GEOD-21138

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-321, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-MEXP-2657, E-GEOD-12773, E-TABM-127, E-GEOD-20540, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-3606, E-GEOD-16363, ... (27 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, E-GEOD-6802 ... (5 experiments)

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662, E-GEOD-7179

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Processing time: 0.516 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM